Literature DB >> 19691926

Atherosclerosis risk factors in systemic lupus erythematosus.

Surabhi Agarwal1, Jennifer R Elliott, Susan Manzi.   

Abstract

Cardiovascular disease (CVD) has emerged as a leading cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Growing evidence suggests that inflammation plays a key role in the pathogenesis of atherosclerosis from initial endothelial dysfunction to rupture of atheromatous plaques. The increased frequency of atherosclerosis in SLE is likely due to a complex interplay among traditional risk factors, disease-related factors such as medications and disease activity, and inflammatory and immunogenic factors. Identification of these novel risk factors will lead to a better understanding of CVD pathogenesis and may also provide targets for potential treatment strategies. When caring for SLE patients, clinicians should be aware of the increased CVD risk and treat the known modifiable risk factors in addition to controlling disease activity and inflammation.

Entities:  

Mesh:

Year:  2009        PMID: 19691926     DOI: 10.1007/s11926-009-0034-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  63 in total

1.  Brachial endothelial function is impaired in patients with systemic lupus erythematosus.

Authors:  Domingos S N Lima; Emilia I Sato; Valter C Lima; Fausto Miranda; Francisca H Hatta
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

Review 2.  The oxidative modification hypothesis of atherosclerosis: does it hold for humans?

Authors:  J L Witztum; D Steinberg
Journal:  Trends Cardiovasc Med       Date:  2001 Apr-May       Impact factor: 6.677

3.  Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages.

Authors:  Y Hasunuma; E Matsuura; Z Makita; T Katahira; S Nishi; T Koike
Journal:  Clin Exp Immunol       Date:  1997-03       Impact factor: 4.330

4.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

Authors:  Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

5.  Risk factors for cardiovascular disease in systemic lupus erythematosus.

Authors:  E Svenungsson; K Jensen-Urstad; M Heimbürger; A Silveira; A Hamsten; U de Faire; J L Witztum; J Frostegård
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

6.  Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.

Authors:  O Vaarala; M Mänttäri; V Manninen; L Tenkanen; M Puurunen; K Aho; T Palosuo
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

7.  Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis.

Authors:  L R Lopez; M Salazar-Paramo; C Palafox-Sanchez; B L Hurley; E Matsuura; I Garcia-De La Torre
Journal:  Lupus       Date:  2006       Impact factor: 2.911

8.  Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis.

Authors:  M Petri; C Lakatta; L Magder; D Goldman
Journal:  Am J Med       Date:  1994-03       Impact factor: 4.965

9.  Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients.

Authors:  M Rath; A Niendorf; T Reblin; M Dietel; H J Krebber; U Beisiegel
Journal:  Arteriosclerosis       Date:  1989 Sep-Oct

10.  Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.

Authors:  Elisabet Svenungsson; Iva Gunnarsson; Guo-Zhong Fei; Ingrid E Lundberg; Lars Klareskog; Johan Frostegård
Journal:  Arthritis Rheum       Date:  2003-09
View more
  10 in total

Review 1.  A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis.

Authors:  Andrew Smyth; Guilherme H M Oliveira; Brian D Lahr; Kent R Bailey; Suzanne M Norby; Vesna D Garovic
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 8.237

2.  SLE with recurrent heart failure and a dermatological clue to another added possibility.

Authors:  Luciano Candilio; David D'Cruz; Divaka Perera
Journal:  BMJ Case Rep       Date:  2011-04-15

3.  Increased expression of human T-cell immunoglobulin- and mucin-domain-containing molecule-4 in peripheral blood mononuclear cells from patients with system lupus erythematosus.

Authors:  Peiqing Zhao; Liyun Xu; Piming Wang; Xiaohong Liang; Jianni Qi; Peng Liu; Chun Guo; Lining Zhang; Chunhong Ma; Lifen Gao
Journal:  Cell Mol Immunol       Date:  2010-02-08       Impact factor: 11.530

Review 4.  Mortality in Systemic Lupus Erythematosus: an Updated Review.

Authors:  César E Fors Nieves; Peter M Izmirly
Journal:  Curr Rheumatol Rep       Date:  2016-04       Impact factor: 4.592

5.  Mortality in patients with systemic lupus erythematosus in Colombia: a case series.

Authors:  David Aguirre-Valencia; Ana Suárez-Avellaneda; Vanessa Ocampo-Piraquive; Iván Posso-Osorio; Juan Naranjo-Escobar; Ivana Nieto-Aristizábal; Gabriel J Tobón; Carlos A Cañas
Journal:  Clin Rheumatol       Date:  2019-04-15       Impact factor: 2.980

6.  Dissecting the immune cell mayhem that drives lupus pathogenesis.

Authors:  Joseph E Craft
Journal:  Sci Transl Med       Date:  2011-03-09       Impact factor: 17.956

7.  Long-Term Outcomes of Systemic Lupus Erythematous Patients after Pregnancy: A Nationwide Population-Based Cohort Study.

Authors:  Ting-Fang Chiu; Ya-Wen Chuang; Cheng-Li Lin; Tung-Min Yu; Mu-Chi Chung; Chi-Yuan Li; Chi-Jung Chung; Wen-Chao Ho
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

8.  Mortality in systemic lupus erythematosus at a teaching hospital in India: A 5-year retrospective study.

Authors:  Gangadharaiah Bharath; Prabhat Kumar; Nayani Makkar; Paras Singla; Manish Soneja; Ashutosh Biswas; Naveet Wig
Journal:  J Family Med Prim Care       Date:  2019-07

Review 9.  High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy.

Authors:  Sang Yeop Kim; Minzhi Yu; Emily E Morin; Jukyung Kang; Mariana J Kaplan; Anna Schwendeman
Journal:  Arthritis Rheumatol       Date:  2019-11-26       Impact factor: 10.995

10.  Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients.

Authors:  Ashira Blazer; Binhuan Wang; Danny Simpson; Tomas Kirchhoff; Sean Heffron; Robert M Clancy; Adriana Heguy; Karina Ray; Matija Snuderl; Jill P Buyon
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.